Airfinity is bringing together some of the leading experts across the life science space for an exclusive roundtable on the role of forecasting in improving disease outcomes and the strategies needed to reduce disease burden.

DO Roundtable (1)

 Pre-emptive Health Economics: How to build population level evidence for events that haven’t happened

Airfinity RNA candidates

Airfinity Launches an RNA Therapeutics and Vaccine Intelligence Tool

World Has 28% Risk of New Covid-Like Pandemic Within 10 Years

Airfinity predicts that treating half of all severely obese patients with metabolic syndrome would see market growth of more than 30X from today’s $2.2bn to $80bn.

i-yunmai-5jctAMjz21A-unsplash

Airfinity forecasts the severely obese population with metabolic syndrome in the US to grow 50% by 2030 from 26 million to 39.1 million people.

LINK 2

Vaccines Need to Stop the Spread of COVID or Protect against New Variants & Other Viruses to Disrupt Market & Reduce Healthcare Burden

The next generation of coronavirus vaccines: a graphical guide

Bill Emmott, former Editor-in-Chief at The Economist, joins Airfinity’s advisory board as the company expands its global public health data offering. 

Bill Emmott by John Cairns 28.4.17-028

Former Editor of The Economist joins Airfinity as advisor 

Our CEO Rasmus Bech Hansen spoke to Bloomberg’s Guy Johnson and Alix Steel about what cuts to testing and restrictions ending could really mean as COVID surges across China.

Screenshot 2022-12-13 at 13.57.16

Airfinity CEO Says Covid Peak Could Go Much Higher

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Analysis by Airfinity shows the AstraZeneca and Pfizer/BioNTech vaccines saved the most lives in the first year of the global vaccination campaign.

Newsroom

Featured